TICKERNERD
Menu
COSMHealthcare · Medical Distribution

COSM Stock Forecast: Cosmos Health, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$0.21
−6.94% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$22.3M
Ticker Nerd rank
19 / 100
Median analyst target
$4.50
Analysts covering
0
Revenue$17.9M+30.7% y/y
Operating income−$2.2M
Net income−$2.8M
Free cash flow−$1.1M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
+3.3%
YTD
−58.5%
1Y
−75.4%
From 52W high
−83.5%
From 52W low
+20.1%
$0.17
$1.25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COSM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cosmos Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Accruals
84
Growth
45
Revisions
31
Momentum
27
Value
19
Quality
13
Issuance
11
Volatility
11

Size (88): Smaller than most of the companies we track.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

COSM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COSM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26COSMHigh $4.50Median $4.50Low $4.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COSM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

COSM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Cosmos Health, Inc. returned −75.4% against +19.6% for the S&P 500, dividends included.

COSM vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Oct 25Jan 26Apr 26Jul 26COSMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COSM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−362.5%
Analysts raising
0
Analysts cutting
1
Fundamentals

Cosmos Health, Inc. (COSM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.4×

Cheaper than 79% of US stocks

Price / sales
0.3×

Cheaper than 89% of US stocks

Price / book
0.5×

Cheaper than 85% of US stocks

EV / EBITDA
−2.2×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
28.8%

Higher than 78% of US stocks

Earnings growth (YoY)
30.7%

Higher than 67% of US stocks

Gross margin
7.7%

Higher than 8% of US stocks

Operating margin
−15.4%

Higher than 23% of US stocks

Net margin
−33.1%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−104.0%

Higher than 13% of US stocks

Return on assets
−18.4%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cosmos Health, Inc. (COSM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cosmos Health, Inc. has a market value of $22.3M and an enterprise value of $36.4M.

  • Revenue in the twelve months to 31 Mar 2026: $69.5M. The latest quarter grew 28.8% year on year.

  • Net income over the same four quarters: −$21.1M, a −30.4% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$9.5M, after $55K of capital spending.

  • Shares outstanding: 49.8M.

  • Trailing P/E: −0.4×; forward P/E: 3.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cosmos Health, Inc. employs 163 people — $426K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

COSM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
COSMCosmos Health, Inc.$22.3M
19
ACHAccendra Health, Inc.$92.7M
44
MEDSDataMeds AI, Inc.$4.2M
15
SNYRSynergy CHC Corp.$1.5M
53
COCPCocrystal Pharma, Inc.*$22.2M
56
BFRIBiofrontera, Inc.*$22.0M
66
ABVCABVC BioPharma, Inc.*$22.6M
14

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cosmos Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest COSM news & analysis

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

GlobeNewsWire · 24 Aug 2026positive

Cosmos Health, Inc. announced projections of over $6 million in annual revenue and $4.3 million in gross profit from its Oliv18™ product across U.S. cardiovascular health and antioxidant categories, as reported by GlobeNewsWire.

Why it matters — This represents a projected revenue and profit contribution from one of the company's products in key U.S. market categories, which is relevant to COSM watchers assessing its commercial pipeline.

Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

GlobeNewsWire · 20 Aug 2026positive

Cosmos Health has entered the Saudi Arabian market through an exclusive distribution agreement with Innova Healthcare. The company secured an initial purchase order for 126,000 Sky Premium Life units, with more than 5 million units expected over the initial five-year term.

Why it matters — This expansion into Saudi Arabia and the multi-year purchase order expectations represent a significant new market opportunity for Cosmos Health's Sky Premium Life product line.

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

GlobeNewsWire · 19 Aug 2026positive

Cosmos Health reported record Q2 2026 revenue of $19.0M (up 29%) and first-half revenue of $36.9M (up 30%), with adjusted gross profit up 58% and adjusted EBITDA improving 13.8%. Total liabilities fell 13.3%, stockholders' equity rose 12.2% to $20.67M, and a $5M share repurchase program is underway.

Why it matters — COSM watchers would note the record revenue across all segments, improved profitability metrics, a strengthened balance sheet, and an active buyback program as signs of continued operational momentum.

Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

GlobeNewsWire · 27 July 2026positive

Cosmos Health announced it is developing a flexible, technology-driven subscription platform for its consumer health products, serving both consumer (B2C) and corporate (B2B) channels, with options including a free nutritionist consultation, an AI-powered assistant, or building a custom package.

Why it matters — The subscription platform represents a significant step in Cosmos Health's technology-driven transformation, expands its revenue channels through both B2C and B2B offerings, and builds on early success with the NOOR Collagen subscription showing a repeat purchase rate above 60%.

FAQ

Frequently asked questions about COSM stock

How does Ticker Nerd's model rank COSM?

As at 22 Aug 2026, Cosmos Health, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

What is the COSM stock forecast for 2030?

No analyst covering Cosmos Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.5 to $4.5 over the next 12 months.

How has COSM stock performed over the past year?

Cosmos Health, Inc. returned -75.4% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cosmos Health, Inc. do?

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group specializing in pharmaceuticals, nutraceuticals, healthcare services, and digital assets.

What is the latest news on COSM?

The most recent item we track (GlobeNewsWire, 24 Aug 2026): "Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories". Cosmos Health, Inc. announced projections of over $6 million in annual revenue and $4.3 million in gross profit from its Oliv18™ product across U.S. cardiovascular health and antioxidant categories, as reported by GlobeNewsWire.

Company

About Cosmos Health, Inc.

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group specializing in pharmaceuticals, nutraceuticals, healthcare services, and digital assets. The company engages in the importation, exportation, distribution, and sale of pharmaceutical products, including over-the-counter drugs, branded and generic medicines, vitamins, minerals, dietary supplements, medical devices, and baby products. It manufactures and markets proprietary brands such as Sky Premium Life, NOOR Collagen, C-Sept, C-Scrub antimicrobial cleansers, and Mediterranation, with operations spanning Europe, the United States, the UK, UAE, and other regions. Cosmos Health Inc. operates manufacturing facilities like Cana Laboratories for contract production, distribution networks including CosmoFarm with robotic automation for pharmacy logistics, and telehealth initiatives. It conducts research and development through platforms like Cloudscreen AI for drug repurposing, focusing on nutraceutical formulas, nanotechnology, and compounds targeting obesity and other disorders. Additionally, the company manages a digital asset treasury featuring Bitcoin and Ethereum holdings to diversify its balance sheet. Serving wholesalers, pharmacies, clinics, retailers like Tesco and Superdrug, and healthcare providers, Cosmos Health Inc. supports a broad ecosystem in wellness and medical distribution. Founded in 2009 and headquartered in Thessaloniki, Greece, it plays a key role in bridging manufacturing, innovation, and global supply chains in the healthcare sector.

CEO Mr. Grigorios Siokas · 163 employees · Greece · https://www.cosmoshealthinc.com